Invivyd Inc
NASDAQ:IVVD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Invivyd Inc
NASDAQ:IVVD
|
US |
|
M3 Inc
OTC:MTHRY
|
JP |
Invivyd Inc
Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is headquartered in Waltham, Massachusetts and currently employs 101 full-time employees. The company went IPO on 2021-08-06. The firm is engaged in developing antibodies to transcend the limits of naturally occurring immunity and provide protection from viral diseases, beginning with COVID-19. Its technology works at the intersection of virology, predictive modeling, and antibody engineering. Its platform approach yields a pipeline of engineered antibodies designed to provide neutralization across past and current SARS-CoV-2 variants of concern, including wildtype, Beta, Delta, and Omicron BA.1, BA.2, BA.5, and BA.2.75. The firm generates a pipeline of products for use in both the prevention and treatment of disease. Its advanced pipeline candidate includes adintrevimab, an investigational monoclonal antibody that is used against multiple variants of concern for the prevention and treatment of COVID-19. The firm also has multiple discovery stage candidates for the prevention of seasonal influenza.
Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is headquartered in Waltham, Massachusetts and currently employs 101 full-time employees. The company went IPO on 2021-08-06. The firm is engaged in developing antibodies to transcend the limits of naturally occurring immunity and provide protection from viral diseases, beginning with COVID-19. Its technology works at the intersection of virology, predictive modeling, and antibody engineering. Its platform approach yields a pipeline of engineered antibodies designed to provide neutralization across past and current SARS-CoV-2 variants of concern, including wildtype, Beta, Delta, and Omicron BA.1, BA.2, BA.5, and BA.2.75. The firm generates a pipeline of products for use in both the prevention and treatment of disease. Its advanced pipeline candidate includes adintrevimab, an investigational monoclonal antibody that is used against multiple variants of concern for the prevention and treatment of COVID-19. The firm also has multiple discovery stage candidates for the prevention of seasonal influenza.
Study enrollment: DECLARATION trial for VYD2311 has reached target enrollment of approximately 1,770 subjects and event accrual is underway.
Timing: Company continues to target mid-2026 for pivotal data readout from DECLARATION, with a prespecified resizing analysis expected around April if needed.
Safety update: The DECLARATION IDMC recommended lifting contraception requirements for women of childbearing potential, allowing pregnant and breastfeeding women to enroll, and removing certain early prespecified safety visits.
Commercial traction: PEMGARDA net revenues for full-year 2025 were $53.4 million; Q4 2025 sales grew 31% sequentially and 25% year-over-year; account reorder rate is 77%.
Balance sheet: Invivyd ended 2025 with $226.7 million in cash and cash equivalents after raising over $200 million in H2 2025, which management says funds the company through anticipated pivotal data and possibly beyond.
Pipeline breadth: Company highlighted new programs and indications — a potent RSV antibody, ongoing measles program update expected H1 2026, and plans to explore monoclonal antibodies for long COVID and post-vaccination syndrome.
Pediatrics focus: Management emphasized strategic interest in pediatric use cases (RSV, measles, COVID prophylaxis / vaccine ‘bridge’ or enhancement) and intent to pursue those populations.
